These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 21404005)

  • 1. A novel antiangiogenic approach for adjuvant therapy of pancreatic carcinoma.
    Joensson P; Hotz B; Buhr HJ; Hotz HG
    Langenbecks Arch Surg; 2011 Apr; 396(4):535-41. PubMed ID: 21404005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.
    Hotz B; Backer MV; Backer JM; Buhr HJ; Hotz HG
    Neoplasia; 2010 Oct; 12(10):797-806. PubMed ID: 20927318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.
    Taeger J; Moser C; Hellerbrand C; Mycielska ME; Glockzin G; Schlitt HJ; Geissler EK; Stoeltzing O; Lang SA
    Mol Cancer Ther; 2011 Nov; 10(11):2157-67. PubMed ID: 21885862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
    Solorzano CC; Baker CH; Bruns CJ; Killion JJ; Ellis LM; Wood J; Fidler IJ
    Cancer Biother Radiopharm; 2001 Oct; 16(5):359-70. PubMed ID: 11776753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
    Pietras K; Hanahan D
    J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of vascular endothelial growth factor blockade and matrix metalloproteinase inhibition as a combination therapy for experimental human pancreatic cancer.
    Hotz HG; Hines OJ; Hotz B; Foitzik T; Buhr HJ; Reber HA
    J Gastrointest Surg; 2003 Feb; 7(2):220-7; discussion 227-8. PubMed ID: 12600446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth.
    Hotz HG; Reber HA; Hotz B; Sanghavi PC; Yu T; Foitzik T; Buhr HJ; Hines OJ
    J Gastrointest Surg; 2001; 5(2):131-8. PubMed ID: 11331474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PKC 412 small-molecule tyrosine kinase inhibitor: single-compound therapy for pancreatic cancer.
    El Fitori J; Su Y; Büchler P; Ludwig R; Giese NA; Büchler MW; Quentmeier H; Hines OJ; Herr I; Friess H
    Cancer; 2007 Oct; 110(7):1457-68. PubMed ID: 17676584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant treatment of pancreatic carcinoma in a clinically adapted mouse resection model.
    Tepel J; Kruse ML; Kapischke M; Haye S; Sipos B; Kremer B; Kalthoff H
    Pancreatology; 2006; 6(3):240-7. PubMed ID: 16543775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorescence-guided surgery, but not bright-light surgery, prevents local recurrence in a pancreatic cancer patient derived orthotopic xenograft (PDOX) model resistant to neoadjuvant chemotherapy (NAC).
    Hiroshima Y; Maawy A; Zhang Y; Murakami T; Momiyama M; Mori R; Matsuyama R; Chishima T; Tanaka K; Ichikawa Y; Endo I; Hoffman RM; Bouvet M
    Pancreatology; 2015; 15(3):295-301. PubMed ID: 25800176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer.
    Hotz HG; Gill PS; Masood R; Hotz B; Buhr HJ; Foitzik T; Hines OJ; Reber HA
    J Gastrointest Surg; 2002; 6(2):159-66; discussion 166. PubMed ID: 11992800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential Impact of Phellinus linteus on Adherence to Adjuvant Treatment After Curative Resection of Pancreatic Ductal Adenocarcinoma: Outcomes of a Propensity Score-Matched Analysis.
    Lee SH; Hwang HK; Kang CM; Lee WJ
    Integr Cancer Ther; 2019; 18():1534735418816825. PubMed ID: 30501431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Photoimmunotherapy lowers recurrence after pancreatic cancer surgery in orthotopic nude mouse models.
    Maawy AA; Hiroshima Y; Zhang Y; Garcia-Guzman M; Luiken GA; Kobayashi H; Hoffman RM; Bouvet M
    J Surg Res; 2015 Jul; 197(1):5-11. PubMed ID: 25799527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
    Takahashi O; Komaki R; Smith PD; Jürgensmeier JM; Ryan A; Bekele BN; Wistuba II; Jacoby JJ; Korshunova MV; Biernacka A; Erez B; Hosho K; Herbst RS; O'Reilly MS
    Clin Cancer Res; 2012 Mar; 18(6):1641-54. PubMed ID: 22275507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer.
    Büchler P; Reber HA; Roth MM; Shiroishi M; Friess H; Hines OJ
    Neoplasia; 2007 Feb; 9(2):119-27. PubMed ID: 17356708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An orthotopic nude mouse model for evaluating pathophysiology and therapy of pancreatic cancer.
    Hotz HG; Reber HA; Hotz B; Yu T; Foitzik T; Buhr HJ; Cortina G; Hines OJ
    Pancreas; 2003 May; 26(4):e89-98. PubMed ID: 12717279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
    Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
    BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SLT-VEGF reduces lung metastases, decreases tumor recurrence, and improves survival in an orthotopic melanoma model.
    Ackerman R; Backer JM; Backer M; Skariah S; Hamby CV
    Toxins (Basel); 2010 Sep; 2(9):2242-57. PubMed ID: 22069683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer.
    Hotz HG; Hines OJ; Masood R; Hotz B; Foitzik T; Buhr HJ; Gill PS; Reber HA
    Surgery; 2005 Feb; 137(2):192-9. PubMed ID: 15674201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.